Advocacy group alleges Sanofi-Shire conspiracy

Share this article:

Shire's March 2012 decision to walk away from the chance to market its drug Replagal in the US and put it in direct competition with Sanofi's Fabrazyme is now being pilloried as a possible conspiracy between the two drugmakers, as opposed to Shire's disinterest in investing in more research for an FDA approval. Both drugs treat the rare condition Fabry disease, in which a specific type of fat accumulates in the cells and can cause kidney and heart disease, among other problems.

The Wall Street Journal reports that a consumer advocacy group alleges that Shire decided to give Sanofi the US market if it would be allowed to sell its drug in Europe, and is asking the Federal Trade Commission to give the situation a once-over.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.